IPHA
Innate Pharma Sets Stage for Catalyst-Rich H2 2026 with Lacutamab, IPH4502, and Monalizumab Updates
On the heels of a strategic partnership with Sobi to advance its lacutamab program in T-cell lymphoma, Innate Pharma has outlined an exciting roadmap for the remainder of 2026. In a recent conference call, the company's CEO, Jonathan Dickinson, highlighted key developments across its focused portfolio that position